Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Decitabine Versus 7+3 Induction in Young Adults With AML
NCT05177731Phase 3Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Investigational ( venetoclax, decitabine) with Standard of Care (Conventional Induction "7+3") (2 arms). Primary endpoint: Overall response rate at 100 days. Started Mar 2022; status: active, not recruiting.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05177731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177731.